BRCA mutation in ovarian cancer: testing, implications and treatment considerations. (August 2017)

• Record Type: Journal Article
• Authors: Neff, Robert T.; Senter, Leigha; Salani, Ritu
• Is Part Of: Therapeutic advances in medical oncology. Volume 9:Number 8(2017)
• Page Start: 519
• Page End: 531
• Publication Date: 2017-08
• Subjects: BRCA -- mutations -- ovarian cancer -- PARP inhibitor; Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.994005
• DOI: 10.1177/1758834017714993
• Languages: English
• ISSNs: 1758-8340

Abstract

Ovarian cancer is a heterogeneous disease that encompasses a number of different cellular subtypes, the most common of which is high-grade serous ovarian cancer (HGSOC). Still today, ovarian cancer is primarily treated with chemotherapy and surgery. Recent advances in the hereditary understanding of this disease have shown a significant role for the BRCA gene. While only a minority of patients with HGSOC will have a germline BRCA mutation, many others may have tumor genetic aberrations within BRCA or other homologous recombination proteins. Genetic screening for these BRCA mutations has allowed improved preventative measures and therapeutic development. This review focuses on the understanding of BRCA mutations and their relationship with ovarian cancer development, as well as future therapeutic targets.